Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00772668 · ClinicalTrials.gov registry record · NA
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
A NA study, sponsored by University of Miami.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT00772668 is a NA study that was terminated before completion, run by University of Miami. The registered enrollment target is 3 participants.
The verdict
NCT00772668, a NA study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving rituximab together with cyclophosphamide, bortezomib, and prednisone may kill more cancer cells. PURPOSE: This clinical trial is studying how well giving rituximab together with cyclophosphamide, bortezomib, and prednisone works as first-line therapy in treating patients with stage III or stage IV follicular lymphoma or marginal zone lymphoma.
Interventions
- DRUG Cyclophosphamide
- DRUG Rituximab
- DRUG Prednisone
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2009-09-25 |
| Est. Completion | 2011-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00772668
The ClinicalTrials.gov registry entry for NCT00772668 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT00772668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00772668 about?
NCT00772668 is a clinical study titled "Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL". RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide and ...
What is the current status of trial NCT00772668?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2009-09-25. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00772668?
The interventions under investigation include: Cyclophosphamide (DRUG), Rituximab (DRUG), Prednisone (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00772668?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.